Khozin, S., Blumenthal, G. M., Jiang, X., He, K., Boyd, K., Murgo, A., . . . Pazdur, R. (2014). U.S. Food and Drug Administration Approval Summary: Erlotinib for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 (L858R) Substitution Mutations. AlphaMed Press.

Khozin, Sean, Gideon M. Blumenthal, Xiaoping Jiang, Kun He, Karen Boyd, Anthony Murgo, Robert Justice, Patricia Keegan, and Richard Pazdur. U.S. Food and Drug Administration Approval Summary: Erlotinib for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 (L858R) Substitution Mutations. AlphaMed Press, 2014.

Khozin, Sean, et al. U.S. Food and Drug Administration Approval Summary: Erlotinib for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 (L858R) Substitution Mutations. AlphaMed Press, 2014.